Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Will breakfast or heartburn pills change how this new drug works?

NCT ID NCT07643272

Knowledge-focused Sponsor: Hutchmed Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 18, 2026 · Updated 4 times

Summary

This early-stage study will enroll 24 healthy adults to find out if food or the stomach-acid-reducing drug rabeprazole changes how the body absorbs an experimental drug called HMPL-760. Participants will take HMPL-760 under different conditions (fasting, with a high-fat meal, with a light meal, or with rabeprazole) and have their blood tested. The results will guide how HMPL-760 should be taken in future studies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HMPL-760 (an experimental drug) and rabeprazole (a stomach acid reducer)
What this could lead to
If successful, this study will help determine how HMPL-760 should be taken (with or without food, and with or without acid-reducing drugs) in future trials.
What could go wrong
This is a very early Phase 1 study in only 24 healthy people, not patients. It is designed to measure drug levels, not to test if the drug works for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

24 people

The number who actually took part.

Started

Jun 2026

Finished

Aug 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants are fully aware of this study and voluntarily sign the ICF. 2. Male or female aged 18 to 45 years old (inclusive). 3. Participant's body mass index (BMI) at screening: 18 kg/m2 \< BMI ≤ 29.9 kg/m2 and weight ≥ 50 kg for males and ≥ 45 kg for females. 4. Participant is willing and able to comply with the protocol in all aspects. Exclusion Criteria: 1. Known history of any gastrointestinal surgery or any condition that could affect drug absorption (e.g., cholecystectomy, achlorhydria, peptic ulcer disease, gastric/intestinal surgery or history of resection; prior appendectomy or hernia repair is allowed). 2. Clinically significant disease within 8 weeks prior to the first dose or clinically significant infection within 4 weeks prior to the first dose. 3. Clinically significant abnormal findings in physical examination, vital signs, or laboratory tests at screening. 4. Systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg at screening. 5. Participants who smoked over 10 cigarettes daily within 3 months before screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy participants are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy participants

Contacts and locations

Locations

  • Shanghai Xuhui Central Hospital

    Shanghai, Shanghai Municipality, 200031, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.